Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Cyclosporine is a steroid-sparing immunosuppressant used in organ and bone marrow transplants as well as inflammatory conditions such as ulcerative colitis, rheumatoid arthritis, and atopic dermatitis. Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions.
- Mechanism
- Curator reviewed · 6 references
Cyclosporine is a calcineurin inhibitor that inhibits T cell activation. Its binding to the receptor cyclophilin-1 inside cells produces a complex known as cyclosporine-cyclophilin. This complex subsequently inhibits calcineurin, which in turn stops the dephosphorylation as well as the activation of the nuclear factor of activated T cells (NF-AT) that normally cause inflammatory reactions. NF-AT is a transcription factor that promotes the production of cytokines such as IL-2, IL-4, interferon-gamma and TNF-alpha, all of which are involved in the inflammatory process. Specifically, the inhibition of IL-2, which is necessary for T cell activation or proliferation, is believed to be responsible for cyclosporine's immunosuppressive actions. In addition to the above, the inhibition of NF-AT leads to lower levels of other factors associated with T helper cell function and thymocyte development.
- Primary indication
- Cyclosporine is approved for a variety of conditions.Curator reviewed · 35 structured indications
- Formula / weight
- C62H111N11O12 · 1202.635 g/mol (avg)
- First approval
- Canada, 1997 · United States, 1983 · European Union, 2020
- Also known as
- Ciclosporin · Cyclosporin · Cyclosporin A · Cyclosporine A
- Code names
- 27-400 · Antibiotic S-7481F1 · NOVA-22007 · NSC-290193 · OL 27-400 · SANG-35 · SDZ-OXL-400
- Brand names
- Cequa
- Gengraf
- Ikervis
- Neoral
- Restasis
- Sandimmune
- Verkazia
- Vevye
Resolves to
PMATZTZNYRCHOR-CGLBZJNRSA-NSMILESCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)CWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Cyclosporine, and which of those have an active Phase 3 trial?